Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Copenhagen, Denmark, 21 December 2021 - Curasight A/S ("Curasight" or the "Company") appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company.
"We are most pleased to have Hanne joining the team at Curasight. With her impressive track-record and in-depth knowledge in drug development and regulatory affairs, she is the perfect choice for the position as Chief Development Officer. Her track-record includes building development organizations in early stage companies - something Curasight will largely benefit from as we expand our clinical portfolio of cancer indications and move into phase III studies and the process towards approval. With Hanne on board, we have strengthened our team and organization to deliver on our ultimate goal - improving the life of cancer patients", says Ulrich Krasilnikoff, CEO of Curasight.
Hanne holds a Master of Science degree in Pharmaceutical Sciences from the University of Copenhagen and an MBA from Copenhagen Business School. She has previously held several managerial positions across different development and regulatory disciplines and positions within clinical oncology development in both smaller and larger pharma companies. Thus, Hanne was the 4[th] employee in Genmab back in in 1999 and with increasing managerial responsibilities over 7 years, building the organization, Hanne was responsible for the drug development project organization with 80 employees in 2007.
In addition to positions held in Genmab, Novo Nordisk, Santaris Pharma, Iolab (Johnson & Johnson) and Azanta, Hanne is also the CEO and founder of ROS Therapeutics. Together, her track-record highlights her valuable knowledge and experience in relation to the strategy that Curasight is in the process of rolling out.
"I am very excited about the new position as CDO. I find Curasight's theranostic technology extremely promising; a technology that has the potential to disrupt the way cancer is diagnosed and treated. Curasight already has a great team and I'm glad to become part of it and the journey towards moving the technology as fast as possible towards clinical use for the benefit of cancer patients", says Hanne Damgaard Jensen.
Curasightscurrent lead indications are aggressive brain cancer (Glioblastoma) within both diagnosis (uTRACE®) and targeted radionuclide therapy (uTREAT®) and prostate cancer diagnosis (uTRACE®) for risk-stratification. The expanded strategy with the potential additional cancer indications will be communicated during Q1.